SCHEMBL30775339

SCHEMBL30775339

Cc1cc(C)nc(OC2CCN(CC(N)=O)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.44
FFAR4 Q5NUL3 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
EGFR P00533 2/20 0.38
OPRK1 P41145 2/20 0.38
ERBB2 P04626 1/20 0.37
TLR9 Q9NR96 2/20 0.37
TLR8 Q9NR97 2/20 0.37
TLR7 Q9NYK1 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775363 0.79 EPHX2 (0.44) ALDH1A1KMT2ATSHRMEN1HTT
SCHEMBL2763758 0.75 MEN1 (0.49) KMT2AMEN1
SCHEMBL2763241 0.72 SMN1; SMN2 (0.51) ALDH1A1KMT2ATSHRMEN1KDM4E
SCHEMBL30775358 0.72 EPHX2 (0.46) ALDH1A1OPRK1
SCHEMBL30775258 0.72 EPHX2 (0.50) ALDH1A1KMT2AMEN1HTTEGFR
SCHEMBL2763577 0.71 OPRK1 (0.56) FFAR4OPRK1MAOAMAOB
SCHEMBL30775177 0.71 L3MBTL1 (0.41) ALDH1A1EGFRKDM4E
SCHEMBL24577905 0.71 KDM4E (0.47) ALDH1A1KMT2ATSHRMEN1EGFR
SCHEMBL15206240 0.70 OPRK1 (0.40) ALDH1A1OPRK1MAOAMAOB
SCHEMBL30775213 0.68 SCN9A (0.39) ALDH1A1EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR LDHA 3499/4885FFAR4 4125/4885ALDH1A1 3927/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR LDHA 3499/4885FFAR4 4125/4885ALDH1A1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.